Fresh look on the urticaria problem.


Cite item

Full Text

Abstract

Introduction. Nowadays urticaria is one of the most common diseases. According to the International Guidelines for the definition, classification, diagnosis and management of urticaria, 2nd-generation H1-antihistamines are recommended to be used as the first-line and second-line therapy. Omalizumab, a humanized monoclonal anti-IgE antibody, is assumed to be the third-line therapy in urticaria treatment.

Summary. In this review we discuss the latest data on pathogenetic mechanisms of urticaria, focusing on the search of the new targets for the therapy. We represent the latest clinical trials of the new biological treatment for urticaria. Safety and efficiency of 4-folds higher therapeutical dose of the 2nd generation H1-antihistamines, and criteria for personalized selection of the antihistamines are discussed.

About the authors

Alla O. Litovkina

NRC Institute of Immunology FMBA of Russia

Author for correspondence.
Email: dr.litovkina@gmail.com
ORCID iD: 0000-0002-5021-9276

graduate student in Department of Skin Allergy and Immunopathology

Russian Federation, 115522, 24 Kashirskoe shosse, Moscow

Eugenii V. Smolnikov

NRC Institute of Immunology FMBA of Russia

Email: qwertil2010@yandex.ru
ORCID iD: 0000-0003-1302-4178

graduate student in Department of Skin Allergy and Immunopathology

Russian Federation, 24, Kashirskoye shosse, Moscow, 115522

Olga G. Elisyutina

NRCI Institute of Immunology FMBA of Russia

Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591

MD, PhD, DSc, leading researcher of the Department of Skin allergy and immunopathology

Russian Federation, 24, Kashirskoye shosse, Moscow, 115522

Elena S. Fedenko

NRS Institute of Immunology FMBA of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242
Scopus Author ID: 6603386923
ResearcherId: P-6912-2015

MD, PhD, DSc, professor, head of the Department of Skin allergy and immunopathology

Russian Federation, 24, Kashirskoye shosse, Moscow, 115522

References

  1. O’Donnell BF. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am. 2014;34(1):89-104. doi: 10.1016/j.iac.2013.09.011.
  2. Delong LK, Culler SD, Saini SS et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35-9. doi: 10.1001/archdermatol.2007.5.
  3. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. doi: 10.1111/all.13397.
  4. Данилычева ИВ, Ильина НИ, Лусс ЛВ, Феденко ЕС, Шульженко АЕ. Федеральные клинические рекомендации. Крапивница. Пересмотр 2018 года. Российский Аллергологический Журнал. 2018;15(5):47-62 [Danilycheva IV, Ilina NI, Luss LV, Fedenko ES, Shulzhenko AE. Federal Clinical Recommendations. Urticaria. Updated, 2018. Russian Journal of Allergy. 2018;15(5):47-62 (in Russian).].
  5. Recto MT, Gabriel MT, Kulthanan K et al. Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clin Mol Allergy. 2017;15(1):19. doi: 10.1186/s12948-017-0074-3.
  6. Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and Angioedema: an Update on Classification and Pathogenesis. Clin Rev Allergy Immunol. 2018;54(1):88-101. doi: 10.1007/s12016-017-8628-1.
  7. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423-432. doi: 10.1111/all.14037.
  8. Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;30:1-13. doi: 10.1159/000507218.
  9. Wang D, Guo S, He H, Gong L, Cui H. Gut microbiome and serum metabolome analyses identify unsaturated fatty acids and butanoate metabolism induced by gut microbiota in patients with chronic spontaneous urticaria. Front Cell Infect Microbiol. 2020;10:24. doi: 10.3389/fcimb.2020.00024.
  10. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, Maurer M. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750. doi: 10.1016/j.jaci.2015.12.1342.
  11. Deza G, Bertolín-Colilla M, Sánchez S, Soto D, Pujol RM, Gimeno R et al. (2018). Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;141(6):2313-2316. doi: 10.1016/j.jaci.2018.02.021.
  12. Kocatürk E, Zuberbier T. New biologics in the treatment of urticaria. Curr Opin Allergy Clin Immunol. 2018;18(5):425-431. doi: 10.1097/ACI.0000000000000466.
  13. Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7:1659-1661. doi: 10.1016/j.jaip.2018.11.018.
  14. Combalia A, Losno RA, Prieto-González S, Mascaró JM. Rituximab in Refractory Chroniс Spontaneous Urticaria: An Encouraging Therapeutic Approach. Skin Pharmacology and Physiology. 2018;31:184-187. doi: 10.1159/000487402.
  15. Magerl M, Terhorst D, Metz M, Altrichter S, Zuberbier T, Maurer M, Bergmann KC. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges. 2018;16(4):477-478. doi: 10.1111/ddg.13481.
  16. Maurer M, Altrichter S, Metz M, Zuberbier T, Church MK, Bergmann KC. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol. 2018;32(3):e112-e113. doi: 10.1111/jdv.14594.
  17. Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol. 2019;33(11):413-415. doi: 10.1111/jdv.15720.
  18. Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E et al. Interactions of bilastine, a new oral H1 antihistamine, with human transporter systems. Drug and Chemical Toxicology. 2012;35(1):8-17. doi: 10.3109/01480545.2012.682653.
  19. Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019;20(1):213. doi: 10.3390/ijms20010213.
  20. Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients. Eur Rev Med Pharmacol Sci. 2018;22(3):820-828. doi: 10.26355/eurrev_201802_14318.
  21. Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R. The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H(1) receptor. Eur J Pharmacol. 2018;838(5):107-111. doi: 10.1016/j.ejphar.2018.09.011.
  22. Antonijoan R, Coimbra J, García-Gea C, Puntes M, Gich I, Campo C et al. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers. Curr Med Res Opin. 2017;33(1):129-136. doi: 10.1080/03007995.2016.1240665.
  23. Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44(4):375-–385. doi: 10.1111/1346-8138.13644.
  24. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921-928. doi: 10.1111/all.12171.
  25. Weller K, Church MK, Hawro T, Altrichter S, Labeaga L, Magerl M et al. Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. Allergy. 2018;73(10):2073-2075. doi: 10.1111/all.13494.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies